Showing 1931-1940 of 4063 results for "".
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Aldeyra Therapeutics Announces Positive Topline Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-data-from-phase-2-dry-eye-chamber-clinical-trial-of-reproxalap-for-dry-eye-disease/2480557/Aldeyra Therapeutics announced positive topline data from a phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25%, an investigational new drug, versus Xiidra (lifitegrast ophthalmic solution 5%) in patients with dry ey
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral Lumevoq Injections at 2-Year Follow-Up of REFLECT Phase 3 Trialhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-2-year-follow-up-of-reflect-phase-3-trial/2480513/GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase 3 clinical trial with Lumevoq. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared
- Surface Ophthalmics Announces First Patient Dosed in Head-to-Head Phase 2 Trial for SURF-100 for Chronic Dry Eye Diseasehttps://modernod.com/news/surface-ophthalmics-announces-first-patient-dosed-in-head-to-head-phase-2-trial-for-surf-100-for-chronic-dry-eye-disease/2478802/Surface Ophthalmics announced that the first patient has been dosed in the phase 2 clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) for the treatment of chronic dry eye disease. SURF-100 utilizes a new an
- Surface Ophthalmics Announces Positive Topline Results From Phase 2 Trial for SURF-201 for the Treatment of Post-Cataract Surgery Pain and Inflammationhttps://modernod.com/news/surface-ophthalmics-announces-positive-topline-results-from-phase-2-trial-for-surf-201-for-the-treatment-of-post-cataract-surgery-pain-and-inflammation/2478781/Surface Ophthalmics announced positive topline results from the phase 2 trial for SURF-201, an investigational therapy for the treatment of post-cataract surgery pain and inflammation. With twice-daily dosing, SURF-201 met its primary endpoints of absence of inflammation at both Day 8 and Day 15.
- AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosahttps://modernod.com/news/agtc-reports-additional-positive-data-from-its-phase-1-2-clinical-trial-in-patients-with-x-linked-retinitis-pigmentosa/2478525/Applied Genetic Technologies Corporation (AGTC) reported positive data from its ongoing phase 1/2 clinical program in patients with X-linked retinitis pigmentosa (XLRP). Visual sensitivity, visual acuity and safety data were reported for 12-month timepoints
- Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)https://modernod.com/news/tepezza-data-from-phase-2-clinical-trial-evaluate-longer-term-responses-in-people-living-with-thyroid-eye-disease-ted/2478415/Horizon Therapeutics announced new long-term follow-up data from the phase 2 clinical trial of Tepezza (teprotumumab-trbw), which showed a sustained response up to 1 year following completion of treatment for Thyroid Eye Disease (TED). These data will be presented as part of the
- Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)https://modernod.com/news/oxurion-nv-reports-first-patient-dosed-in-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme/2478228/Oxurion NV reported that the first patient has been dosed in its two-part phase 2 study (“KALAHARI”) evaluating THR-149 for the treatment of DME. THR-149 acts through inhibition of the Plasma Kallikrein-Kinin (PKaI-Kinin) system, a validated VEGF independent target for DME. In a phase 1 st
- ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Updatehttps://modernod.com/news/proqr-announces-positive-findings-from-an-interim-analysis-in-the-phase-1-2-trial-of-qr-421a-for-usher-syndrome-and-provides-business-update/2477500/ProQR Therapeutics announced positive findings from a planned 3-month interim analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. The company is also providing an update